AI could spot liver cancer early in hepatitis b patients
NCT ID NCT07160946
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will enroll 6000 people with hepatitis B who are at high risk for liver cancer. Researchers will use an AI system to analyze health data and track participants over time. The goal is to see if AI can help catch liver cancer earlier than current methods.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AI follow-up system
- What this could lead to
- If successful, this could lead to a more accurate way to predict and catch liver cancer early in people with hepatitis B, potentially saving lives through earlier treatment.
- What could go wrong
- This is an observational study, not a treatment trial. The AI system may not improve outcomes, and results may not apply to all populations. It is still early and large-scale validation is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV-RELATED LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Third Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510630, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.